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Rationale: Abnormal inflammation and accelerated decline in lung
function occur in patients with chronic obstructive pulmonary dis-
ease (COPD). Human sirtuin (SIRT1), an antiaging and antiinflam-
matory protein, is a metabolic NAD1-dependent protein/histone
deacetylase that regulates proinflammatory mediators by deacety-
lating histone and nonhistone proteins.
Objectives: To determine the expression of SIRT1 in lungs of smokers
and patients with COPD, and to elucidate the regulation of SIRT1 in
response to cigarette smoke in macrophages, and its impact on
nuclear factor (NF)-kB regulation.
Methods: SIRT1 and NF-kB levels were assessed in lung samples of
nonsmokers, smokers, and patients with COPD. Human monocyte–
macrophage cells (MonoMac6) were treated with cigarette smoke
extract (CSE) to determine the mechanism of CSE-mediated regula-
tion of SIRT1 and its involvement in RelA/p65 regulation and IL-8
release.
Measurements and Main Results: Peripheral lungs of smokers and
patients with COPD showed decreased levels of nuclear SIRT1, as
compared with nonsmokers, associated with its post-translational
modifications (formation of nitrotyrosine and aldehyde carbonyl
adducts). TreatmentofMonoMac6 cellswithCSE showeddecreased
levels of SIRT1 associatedwith increasedacetylationof RelA/p65NF-
kB. Mutation or knockdown of SIRT1 resulted in increased acetyla-
tion of nuclear RelA/p65 and IL-8 release,whereas overexpressionof
SIRT1 decreased IL-8 release in response to CSE treatment in
MonoMac6 cells.
Conclusions: SIRT1 levels were reduced inmacrophages and lungs of
smokers and patients with COPD due to its post-translational mod-
ifications by cigarette smoke–derived reactive components, leading
to increased acetylation of RelA/p65. Thus, SIRT1 plays a pivotal role
in regulation of NF-kB–dependent proinflammatory mediators in
lungs of smokers and patients with COPD.
Keywords: reactive oxygen species; acetylation; nuclear factor-kB;
inflammation; deacetylases
Chronic obstructive pulmonary disease (COPD) is a major cause
of disability, morbidity, and mortality in smokers. It is charac-
terized by progressive and largely irreversible airflow limitation,
which is associated with an abnormal inflammatory response in
the lung (1–3). Cigarette smoking is the primary cause of COPD
characterized by accelerated decline in lung function and alveolar
destruction of the lung (3, 4). The inflammatory changes that oc-
cur in COPD are also seen in cigarette smokers without COPD,
but to a lesser extent (5, 6). COPD is linked with the aging pro-
cess of the lungs due to its direct encounter with inhaled cigarette
smoke (CS)–derived oxidants and free radicals and other organic
constituents (3, 4, 7). It is well known that abnormal inflamma-
tory responses to smoking in patients with COPD are due to
chronic inflammatory effects incited by CS (6, 8). However, due
to the complex nature of the mechanism(s) of the inflammatory
processes in COPD (6, 8), the precise molecular mechanisms
whereby CS triggers abnormal and sustained lung inflammation
and aging process still remain unclear.
The metabolic nicotinamide adenine dinucleotide (NAD1)–
dependent protein deacetylases have emerged as important reg-
ulators of chronic inflammatory diseases, cancer, and aging (9).
These proteins, which belong to class III histone/protein deace-
tylases (HDACs), are referred to as sirtuins. The founding mem-
ber, ySir2 (yeast silent information regulator 2), homologous
to human sirtuin 1 (SIRT1), is essential for maintaining silent
chromatin via the deacetylation of histones. Activation or over-
expression of SIRT1 has been shown to increase the lifespan of fly
(Drosophila), yeast (Saccharomyces cerevisiae), worm (Caeno-
rhabditis elegans) (up to 70%), and mouse (strain C57BL/6J)
(10–15). Recently, it has been shown that SIRT1 plays an im-
portant role in a wide variety of processes, including stress re-
sistance, metabolism, apoptosis, senescence, differentiation, and
aging (9).
SIRT1 negatively regulates transcription factors, such as nu-
clear factor (NF)-kB, in the nucleus by the deacetylation of mod-
ified lysine residues on histones, transcription factors, and other
nonhistone proteins (16–18). Recently, it has been shown that
SIRT1 regulates NF-kB–dependent transcription and cell sur-
vival in response to tumor necrosis factor (TNF)-a (19). It has
been suggested that SIRT1 deacetylase may directly bind to one
or more constituents in the chromatin complex, resulting in
structural reorganization, and therefore has the ability to estab-
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Sirtuin (SIRT1) deacetylase is an antiaging and antiinflam-
matory protein. Cigarette smoke reduced SIRT1 levels by
post-translational modifications, leading to acetylation of
the RelA/p65 subunit of nuclear factor-kB.
What This Study Adds to the Field
SIRT1 deacetylase is decreased in macrophages, and in
lungs of smokers and patients with chronic obstructive
pulmonary disease.
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lish silent chromatin domains (17). Evidence indicates that
sirtuins have evolved to mediate signaling initiated by stress
conditions such as metabolic alterations/nutritional deprivation
and calorie restriction (20). However, environmental stress, such
as CS exposure, has been shown to decrease the levels of SIRT1
dramatically both inmacrophages in vitro and in rat lungs in vivo.
This reduction has also been found to be associated with in-
creased proinflammatory cytokine release (21). However, the
regulation of SIRT1 in the lungs of smokers and patients with
COPD, and its role in regulation of NF-kB–dependent proin-
flammatory cytokines is unknown.
The pathophysiology of COPD is multifactorial, with an
inflammatory cell profile that includesmacrophages, neutrophils,
andT lymphocytes (6, 8, 22, 23).Macrophages are one of themost
predominant inflammatory cell types involved in chronic inflam-
matory states, such as COPD, since they secrete both neutrophil
and macrophage chemotactic factors, and related chemokines,
andmatrixmetalloproteases (6, 24). The influx ofmacrophages in
the lungs by cigarette smoking leads to increased expression of
proinflammatory cytokines (24), which is now recognized to be an
outcome of chromatin remodeling due to altered acetylation/
deacetylation of histone proteins (25, 26). Therefore, the involve-
ment of sirtuin in the regulation of proinflammatory cytokine
gene expression by deacetylation of NF-kB subunit(s) in human
macrophages appears to be highly possible. In light of this, we
therefore hypothesized that SIRT1 regulates NF-kB–dependent
proinflammatory cytokines in the lungs of smokers and patients
with COPD, and that its function is altered by post-translational
modifications by reactive components of CS. We therefore stud-
ied the levels and expression of SIRT1 in peripheral lungs of
smokers with and without COPD, and determined the molecular
regulation of SIRT1 by CS exposure in a monocyte–macrophage
cell line (MonoMac6 cells). In addition, the role of SIRT1 in the
regulation of proinflammatory cytokine release was also investi-
gated.
METHODS
Materials
Unless otherwise stated, all reagents used in this study were purchased
fromSigma (St. Louis,MO). Penicillin, streptomycin, andRPMI (Roswell
Park Memorial Institute) 1640 were obtained from Life Technologies
(Gaithersburg, MD). Rabbit polyclonal anti-SIRT1 (cat. no. Ab7343) and
mouse monoclonal anti-SIRT1 (cat. no. 05-707) antibodies were pro-
cured from Abcam (Cambridge, MA) and Upstate (Lake Placid, NY),
respectively. Antibodies against NF-kB–RelA/p65 (rabbit polyclonal;
cat. no. sc-372), laminB (goat polyclonal; sc-6216), anda-tubulin (mouse
monoclonal; cat. no. sc-5286) were purchased from Santa Cruz Bio-
technology (Santa Cruz, CA). Mouse monoclonal antibodies against 4-
hydroxy-2-nonenal (cat. no. 24327), nitrotyrosine (cat. no. 05-233), and
b-actin (cat. no. CP01) were obtained from Oxis International (Foster
City, CA), Upstate, and Calbiochem (La Jolla, CA), respectively.
Human SIRT1 siRNA (cat. no. L-003540-00), nontarget scrambled
siRNA (cat. no. D-001810-01) and DharmaFECT2 transfection reagent
(cat. no. T-2002-01) were purchased from Dharmacon (Lafayette, CO).
The antiacetylated RelA/p65 (AcK310) antibody (33) was provided
by Dr. Leonard Buckbinder at Pfizer Global R&D (Groton, CT).
OverexpressionSIRT1plasmidandSIRT1 construct lackingdeacetylase
domain (SIRT1-H363Y) were obtained from Addgene (Cambridge,
MA).
Collection of Human Lung Tissues
Lung tissue specimens from 37 subjects/patients including 10 lifelong
nonsmokers, 10 current smokers with normal lung function, and 9
patients with COPD (3 former and 6 current smokers; 2 patients had
been prescribed inhaled steroids) undergoing resection for suspected
lung tumor (either malignant or nonmalignant–local carcinoma or
hamartoma), and 8 patients (former smokers; all had been prescribed
inhaled and/or low-dosage oral corticosteroids) with severe COPD
undergoing lung transplantation were collected (both COPD groups
were pooled; see Table 1) from the Departments of Medicine and
Pathology, Helsinki University Hospital. COPD was defined according
to GOLD (Global Initiative for Chronic Obstructive Lung Disease)
criteria (FEV1 , 80% of predicted, FEV1/FVC , 70% and bronchodi-
latation effect, 12%) (1). None of the patients had suffered from acute
exacerbation for 2 months. Tumor-free peripheral lung tissues were
immediately stored at2808C forWestern blot analysis and preserved for
immunohistochemistry as described by Dail and colleagues (27). The
clinical characteristics of the patients are shown in Table 1.
MonoMac6 Cell Culture
Monocyte–macrophage cell line (maturemonocytes)MonoMac6, which
was established from peripheral blood of a patient with monoblastic
leukemia (28, 29), was grown in RPMI 1640 medium supplemented with
10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 mg/ml penicillin,
100 U/ml streptomycin, 1% nonessential amino acids, 1 mM sodium
pyruvate, 1 mg/ml human holo-transferrin, 8 mg/ml polymixin B, 9 mg/ml
bovine insulin, and 1 mM oxaloacetic acid. The cells were cultured at
378C in a humidified atmosphere containing 7.5% CO2.
Preparation of CS Extract
CS extract (CSE) (10%) was prepared by bubbling smoke from one
research grade cigarette (1R3F; University of Kentucky, Lexington,
KY) into 10 ml of RPMI 1640 medium with 1% FBS, as described
previously (21, 30, 31). See the online supplement for further details.
In Vitro Treatments
MonoMac6 cells were seeded at a density of 1.5 3 106 cells/well in six-
well plates containing 2 ml of culture medium supplemented with 1%
FBS, starved overnight, and then treated with different concentrations
of CSE (0.1, 0.5, and 1.0%) at 378C. After 1, 4, or 24 hours of treat-
ment, the cells and culture media were harvested.
Experimental Procedures
The detailed procedures for Western blotting, immunoprecipitation,
immunohistochemistry, immunocytochemistry, mRNA expression, and
siRNA or cDNA transfection are provided in the online supplement.
Statistical Analysis
Statistical analysis of significance was calculated by one-way analysis of
variance followed by Tukey’s post hoc test, using StatView software
(SAS Institute Inc., Cary, NC). Results are shown as mean 6 SEM of
at least three independent experiments.
Ethical Considerations
The study was approved by the ethics committee of Helsinki University
Hospital District. The volunteers gave their written, informed consent.
TABLE 1. SUMMARY OF THE CLINICAL CHARACTERISTICS OF
SUBJECTS AND PATIENTS
Nonsmokers Smokers COPD
Number 10 10 17
M:F ratio 6:4 8:2 9:8
Age, yr 59 6 15 58 6 4 60 6 7
Smoking, pack-years 0 34 6 18* 42 6 19*
FEV1% predicted 98 6 4 97 6 13 39 6 27
†
FEV1/FVC, % 81 6 3 81 6 2 51 6 23
‡
DLCO, % predicted 80 6 12 90 6 10 54 6 23
‡
DLCO/VA, % predicted 86 6 14 103 6 13 70 6 24
Definition of abbreviations: COPD 5 chronic obstructive pulmonary disease;
DLCO 5 diffusing capacity of lung for carbon monoxide; M:F 5 male:female.
Data shown represents mean 6 SEM unless otherwise indicated.
* P , 0.001 compared with nonsmokers.
† P , 0.001 compared with nonsmokers and smokers without COPD.
‡ P , 0.05 compared with nonsmokers and smokers without COPD.
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RESULTS
Decreased Levels of Nuclear SIRT1 in Peripheral Lung Tissues
of Smokers and Patients with COPD Were Associated with
Increased Post-translational Modifications by Reactive
Aldehydes and Nitric Oxide Products
To determine the levels of SIRT1, the peripheral lung samples
were collected from nonsmokers, smokers, and patients with
COPD. Levels of nuclear SIRT1 were measured by Western
blotting and normalized with the amount of b-actin (loading
control). The levels were significantly lower (P , 0.001) in
nuclear extracts of peripheral lung tissues of smokers and pa-
tients with COPD than in the lungs of nonsmokers (Figures
1A and 1B). The reduction in the levels of SIRT1 was more
pronounced in patients with COPD compared with that of
smokers. Similar reduction in SIRT1 activity was also observed
in nuclear extracts (data not shown). In view of the presence of
prooxidative and nitrosative components in CS and our obser-
vation of decreased SIRT1 levels in response to CSE (see
above), we investigated whether oxidative/nitrosative protein
modifications are involved in the observed reduction in SIRT1
levels. Post-translational/covalent modification of SIRT1 pro-
teins was assessed by immunoprecipitation, followed by West-
ern blot analysis using monoclonal antibodies for 4-hydroxy-2-
nonenal (4-HNE) and 3-nitrotyrosine. There was a significant
increase in tyrosine nitration and 4-HNE (carbonyl adducts)
modification on SIRT1 in lungs of smokers and patients with
COPD compared with nonsmokers (Figures 1C and 1D).
Immunohistochemical staining of fixed peripheral lung tis-
sues confirmed the decrease in the levels of SIRT1 in macro-
phages and airway/alveolar epithelial cells both in the lungs of
smokers and in patients with COPD when compared with
nonsmokers (Figures 2A and 2B). These data suggest that the
level of SIRT1 is decreased by oxidative and/or proinflamma-
tory effects of CS both in smokers and in patients with COPD.
Decreased Level of SIRT1 Was Associated with Increased
Activation of RelA/p65 NF-kB in the Lungs of Smokers and
Patients with COPD
To determine whether decreased levels of SIRT1 are associated
with the expression of NF-kB–dependent proinflammatory
cytokines, the level of RelA/p65 subunit of NF-kB was assessed
in the peripheral lung tissues of smokers and patients with
COPD, and compared with nonsmokers. The expression of NF-
kB was increased in lung macrophages and epithelial cells of
smokers and patients with COPD as compared with non-
smokers (Figures 3A and 3B), suggesting that SIRT1 reduction
is associated with NF-kB activation.
SIRT1 Protein Levels and mRNA Expression Were Reduced by
CSE Treatment in MonoMac6 Cells
Todetermine themolecular regulation of decreased SIRT1 levels
in lungs (predominantly inmacrophages) of smokers and patients
with COPD, the effect of CSE on SIRT1 levels was investigated
in a human monocyte–macrophage cell line (MonoMac6). CSE
(0.1, 0.5, and 1.0%) decreased nuclear SIRT1 protein levels at 4
and 24 hours of treatment (Figures 4A and 4B). Similar reduction
in SIRT1 activity was also observed in response to CSE treat-
ments in MonoMac6 cells (data not shown). To further charac-
terize the mechanism of CS-mediated decrease in SIRT1 levels,
we examined the level of SIRT1 mRNA in CSE-treated Mono-
Mac6 cells using qualitative reverse transcriptase–polymerase
chain reaction (RT-PCR). CSE produced marked decreases in
SIRT1 mRNA levels in macrophages at 24 hours but not at 4
hours (Figure 4C). Immunocytochemical staining for SIRT1 con-
firmed the localization of SIRT1 in the nucleus of MonoMac6
Figure 1. Decreased levels of
sirtuin (SIRT1) protein in lung
tissue of smokers and patients
with chronic obstructive pul-
monary disease (COPD). (A)
Western blot analysis of SIRT1
in soluble nuclear proteins (30
mg) extracted from the lung
tissue of nonsmokers (n 5 10),
smokers (n5 10), and patients
with COPD (n 5 17). The
proteins were electrophoresed
on a 7.5% polyacrylamide gel
electrophoresis and electro-
blotted onto a nitrocellulose
membrane. The level of SIRT1
protein was determined using
mouse monoclonal anti-SIRT1
antibody. The purity of nuclear
extract was shown by the pres-
ence of lamin B (nuclear enve-
lope protein) and the absence
of the cytoskeletal protein a-
tubulin (not shown). (B) After
densitometric analysis, the val-
ues were normalized against the loading control, b-actin. The relative level (% of control) of SIRT1 showed decreased levels of nuclear SIRT1 protein
in the lung tissues of smokers and patients with COPD. (C ) SIRT1 protein was immunoprecipitated from the nuclear extract of lung homogenates.
The levels of SIRT1 adducts with 4-hydroxy-2-nonenol (4-HNE) and nitration of tyrosine residues on SIRT1 were analyzed by immunoblotting with
anti–4-HNE and anti–3-nitrotyrosine (3-NT) antibodies, respectively. Equal amount of immunoprecipitated SIRT1 protein (100 mg) was used for
Western blotting. (D) Relative intensity of 4-HNE/SIRT1 and 3-NT/SIRT1 represents the increased post-translational modifications of SIRT1 protein in
lungs of smokers and patients with COPD compared with nonsmokers. A representative blot is shown, which was obtained from several blotting
experiments. Results are expressed as mean 6 SEM. ***P , 0.001, significant compared with nonsmokers.
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cells, which were dramatically decreased in response to CSE
treatments (Figures 5A and 5B). This finding suggests that CS-
mediated modification of SIRT1 occurs at earlier time points
(4 h), which leads to its degradation, whereas the reduction of
mRNA level occurs at later time points (24 h). This finding
corroborates with our results that CSE decreased SIRT1 protein
levels in MonoMac6 cells at 4 hours. Thus, it appears that
decrease in SIRT1 levels/enzyme activity due to CS (post-trans-
lational effect) might precede the transcriptional effects (see
below).
Figure 2. Decreased staining
of sirtuin (SIRT1) in lung mac-
rophages and alveolar/airway
epithelial cells of smokers with
and without chronic obstruc-
tive pulmonary disease (COPD).
(A) Representative photographs
(original magnification, 3400)
from immunostaining for SIRT1
in lung tissues from nonsmokers
(n5 10) and smokers with (n5
17) and without (n 5 10)
COPD. The levels of SIRT1 were
measured in the fixed lung sec-
tions (3-mm thick) by immu-
nohistochemical staining using
rabbit polyclonal anti-SIRT1 anti-
body (1:100 dilution) with av-
idin–biotin–peroxidase com-
plex method followed by
hematoxylin counter staining.
Dark brown color represents the
presence of SIRT1 (indicated
with thick arrow), which was
decreased in smokers’ lung (in-
dicated with thin arrow). Alv 5
alveoli; Aw 5 airway; E 5 epi-
thelial cells; M 5 macrophage.
(B) Immunostaining scores for
SIRT1 per cell type in alveolar
and airway regions of the lung.
The assessment of immunos-
taining intensity was performed
semiquantitatively and in a
blinded fashion. Solid bars, in-
tense staining; shaded bars, moderate/weak staining; open bars, no staining. Results are represented as mean 6 SEM. ***P , 0.001, significant
compared with nonsmokers.
Figure 3. Decreased levels of sirtuin
(SIRT1) in smokers and patients with
chronic obstructive pulmonary disease
(COPD) were associated with increased
levels of RelA/p65 nuclear factor (NF)-kB.
The expression of NF-kB was measured in
fixed lung sections (3-mm thick) of non-
smokers (n 5 10), and smokers with (n 5
17) andwithout (n5 10) COPD by immu-
nohistochemical staining using anti-RelA/
p65 NF-kB antibody (1:100 dilution) fol-
lowed by incubations with fluorescein
isothiocyanate conjugated anti-rabbit sec-
ondary antibody. Representative immuno-
fluorescent images (originalmagnification,
3400) showed increased levels of NF-kB in
the lungs (especially in macrophages and
epithelial cells) of smokers with and with-
out COPD as compared with nonsmokers.
Arrows indicate the cells (airway/alveolar
epithelial cells and macrophages) that ex-
press increased levels of RelA/p65 NF-kB
proteins. (B) Immunostaining score for RelA/p65 was performed semiquantitatively and in a blinded fashion: 0 5 no staining, 1 5 weak staining, 2 5
moderate staining, 35 intense staining. Results are expressed as mean6 SEM. ***P, 0.001, significant compared with nonsmokers.
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CSE Induced IL-8 Release in MonoMac6 Cells
To determine the effect of CS on proinflammatory cytokine
release in vitro, MonoMac6 cells were exposed to different
concentrations of CSE. Culture media were collected to assay
the IL-8 release by ELISA. CSE (0.1, 0.5, and 1.0%) significantly
increased IL-8 release from these cells at 4 (P, 0.01 orP, 0.001)
and 24 hours (P, 0.001) of treatment (Figure 6). Assay of lactate
dehydrogenase leakage showed no cytotoxicity of CSE (0.1–
1.0%) in MonoMac6 cells at 4 and 24 hours. These results
confirmed the proinflammatory effect of CS, and the increased
release of proinflammatory cytokines was associated with de-
creased levels of SIRT1 in MonoMac6 cells.
SIRT1 Deacetylase Regulates IL-8 Release from MonoMac6
Cells in Response to CSE
To characterize the role of SIRT1 in CS-mediated IL-8 release,
we knocked down the endogenous SIRT1, overexpressed SIRT1
or its mutant lacking catalytic activity (SIRT1 H363Y lacking
deacetylase domain) inMonoMac6 cells, whichwere then treated
with CSE (0.5%) for 4 or 12 hours. SIRT1 levels were decreased
by SIRT1 siRNA transfection (z60%, data not shown; without
any change in SIRT2 or SIRT3 levels) and/or CSE treatment.
Knockdown of SIRT1 or CSE treatment resulted in significantly
(P , 0.001) increased IL-8 release in MonoMac6 cells as
compared with control and nonscrambled siRNA transfected
groups. There was a further increase in the level of IL-8 release
in CSE-treated SIRT1 siRNA-transfected cells as compared with
CSE-treated cells alone (Figure 7A).Overexpressionof SIRT1or
H363Y did not show any significant change in IL-8 release at
4 hours, but in response to CSE treatment, overexpression of
SIRT1 decreased the IL-8 release, whereas H363Y increased the
IL-8 release as compared with the CSE-treated group (Figure
7B). Taken together, these data show a negative trend in the
levels/deacetylase activity of SIRT1 and IL-8 release, further
confirming the involvement of SIRT1 in CS-mediated IL-8
release.
Figure 4. Decreased levels of sirtuin (SIRT1) pro-
tein and mRNA expression by cigarette smoke
extract (CSE) treatment in monocyte–macrophage
(MonoMac6) cells. (A) Western blots of soluble
nuclear proteins (30 mg) extracted from CSE-
exposed MonoMac6 cells. Expression of SIRT1
was determined using mouse monoclonal anti-
SIRT1 antibody. The purity of nuclear extract was
shown by the presence of lamin B (nuclear enve-
lope protein) and the absence of the cytoskeletal
protein a-tubulin (bands not shown). Gel pictures
shown are representative of at least three separate
experiments. (B) Densitometric values of SIRT1 were
normalized against the loading control, b-actin.
The relative level (% of control) of SIRT1 in Mono-
Mac6 cells showed decreased levels of SIRT1 pro-
tein in response to CSE at 4 and 24 hours. (C ) CSE
decreased the levels of SIRT1 mRNA in MonoMac6
cells. After 4 and 24 hours of CSE treatment, total
RNA was extracted from MonoMac6 cells using
RNeasy kit (Qiagen, Germantown, MD). Reverse
transcriptase–polymerase chain reaction was per-
formed. Amplified products (SIRT1: 200 bp;
GAPDH: 600 bp) were resolved by 1.5% agarose
gel electrophoresis, stained with ethidium bromide.
SIRT1 mRNA expression was decreased after 24-
hour exposure to low concentrations of CSE (0.5
and 1%) compared with control. Data represent
mean 6 SEM of three experiments (n 5 3). *P ,
0.05, **P , 0.01, ***P , 0.001, significant com-
pared with control values.
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SIRT1 Is Post-translationally Modified by CSE-derived Reactive
Oxygen/Nitrogen Species and Reactive Aldehydes in
MonoMac6 Cells
Based on above data of post-translationalmodifications of SIRT1
by reactive aldehydes and nitric oxide in lungs of smokers and
patients with COPD, we determined whether CSE is directly
involved in such modifications by its reactive components in
MonoMac6 cells. Indeed, our data show post-translational mod-
ification of SIRT1 protein by 4-HNE and 3-nitrotyrosine in
response to CSE in MonoMac6 cells, confirming the direct
involvement of CS components, rather than inflammatory cell
reactive oxygen species (ROS) production, in covalent modifica-
tion of SIRT1 (Figures 8A and 8B).
CS-mediated Reduction of SIRT1 Was Associated with
Increased Acetylation and Activation of RelA/p65 NF-kB
To examine the relationship between CSE-mediated acetylation/
activation of NF-kB and IL-8 release, MonoMac6 cells were
treated with CSE (0.5 and 1.0%) and analyzed for acetylated
RelA/p65 using a specific acetylated lysine 310 residue (K310)
antibody for RelA/p65. Acetylation of RelA/p65 at lysine 310
residue is critical for sustained proinflammatory cytokine re-
lease (32, 33). Western blot analysis revealed that CSE sig-
nificantly increased the acetylation and thereby activation of
RelA/p65 (Figures 9A and 9B). CSE treatment decreased the
SIRT1 deacetylase level (Figures 4 and 5), which was associated
with increased acetylation of RelA/p65 levels in the nucleus of
MonoMac6 cells.
Depletion of SIRT1 Leads to Augmentation of CSE-mediated
Acetylation of RelA/p65 NF-kB
Further experiments were performed to determine whether
SIRT1 regulates acetylation/activation of NF-kB, because it is
known that SIRT1 interacts with RelA/p65 NF-kB (21), and the
depletion of SIRT1 was associated with increased expression of
RelA/p65 NF-kB in the peripheral lungs of smokers and patients
with COPD (Figure 3). SIRT1 knockdown alone significantly
(P , 0.001) increased the acetylation of RelA/p65 NF-kB in
MonoMac6 cells. In combination with CSE treatment, SIRT1
knockdown augmented the acetylating effect of CSE on RelA/
p65 (Figures 10A and 10B). This suggested that SIRT1 regulates
the acetylation and activation of RelA/p65 NF-kB (lysine 310
residue) in the nucleus.
DISCUSSION
Recent focus on COPD research is to understand the factors or
molecular mechanisms involved in underlying pathogenesis of
lung inflammation in smokers who are susceptible to COPD.We
have previously shown that proinflammatory cytokine release
was increased in a human monocytic–macrophage cell line
Figure 5. Decreased sirtuin (SIRT1) protein
staining in response to cigarette smoke extract
(CSE) treatment in monocyte–macrophage
(MonoMac6) cells. (A) CSE decreased the levels
of SIRT1 in MonoMac6 cells at 4 and 24 hours.
MonoMac6 cells were treated with different
concentrations of CSE (0.1–1.0%). Cells were
harvested and the cytospin slides were prepared
at 4 and24hours of treatments. Immunostaining
was performed using a rabbit polyclonal anti-
body specific for SIRT1 followed by the avidin–
biotin–peroxidase complex method, and coun-
terstained with hematoxylin. The dark brown
color represents the presence of SIRT1, which
was decreased in response to CSE treatment. (B)
Graph showing the percentage of SIRT1-positive
cells from the total number of cells in CSE-treated
MonoMac6 cells. The assessment of immunos-
taining intensity was performed semiquantita-
tively and in a blinded fashion. Results shown are
means6 SEMof three separate experiments (n5
3). ***P , 0.001, significant compared with
control values.
Figure 6. Cigarette smoke extract (CSE) induced IL-8 release from
monocyte–macrophage (MonoMac6) cells. MonoMac6 cells were trea-
ted with freshly prepared CSE (0.1, 0.5, and 1.0%) for 4 and 24 hours.
IL-8 release was measured in the culture media by sandwich ELISA duo-
antibody kit (R&D Systems, Minneapolis, MN). CSE showed increase in
the levels of IL-8 as compared with controls at 4 and 24 hours. Each
histogram represents the mean 6 SEM of three experiments (n 5 3).
**P, 0.01, ***P, 0.001, significant compared with controls.
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(MonoMac6) in vitro and in rat lung in vivo in response to CS
exposure (21, 34). This was associated with increased NF-kB
activation and acetylation of histone proteins (25, 31). However,
the molecular mechanisms of CS-mediated lung inflammation,
particularly in patients with COPD, are not completely under-
stood. This studywas focused on the role of class III deacetylases,
SIRT1, which is an important protein involved in deacetylation
of proteins/histones, regulation of proinflammatory cytokine
release, apoptosis, stress resistance, metabolism, senescence,
differentiation, and aging (19, 21, 35, 36)—all of which are linked
to the pathogenesis of COPD (4–6, 8, 24). The levels of SIRT1
were decreased in peripheral lungs, particularly in alveolar
macrophages, airway epithelium, and in alveolar epithelium of
smokers and patients with COPD as compared with nonsmokers.
Because SIRT1 is involved in the regulation of NF-kB (19, 21),
Figure 7. Cigarette smoke extract
(CSE)–mediated IL-8 release was
modified by sirtuin (SIRT1) knock-
down,mutation, and overexpression
in monocyte–macrophage (Mono-
Mac6) cells. (A) MonoMac6 cells
were transfected with predesigned
human SIRT1 siRNA or scrambled
nontarget siRNA using Dharma-
Fect2 siRNA transfection reagent.
After 36–48 hours of transfection
(cells . 85% viable), the cells were
treated with CSE (0.5%) for 12
hours. At the end of the experiment,
culture media was collected by cen-
trifugation for IL-8 assay. SIRT1
knockdown led to significant increase in IL-8 release in response to CSE treatment in MonoMac6 cells as compared with nontarget scrambled siRNA.
(B) MonoMac6 cells were transfected with SIRT1 overexpressing plasmid or SIRT1-H363Y (mutated in the deacetylase domain) using the calcium
phosphate method. Overexpression of SIRT1 deceased IL-8 release, whereas SIRT1-H363Y lacking SIRT1 deacetylase domain increased IL-8 release in
response to CSE treatment at 4 hours. Each value is the mean 6 SEM of triplicate determinations (n 5 3). **P , 0.001, ***P , 0.001, significant
compared with control; ##P, 0.01, ###P, 0.001, significant compared with CSE-treated group.
Figure 8. Cigarette smoke extract (CSE) caused post-translational
modifications of sirtuin (SIRT1). (A) SIRT1 protein was immunoprecipi-
tated from the nuclear extract of monocyte–macrophage (MonoMac6)
cells treated with CSE (0.1, 0.5, and 1.0%) for 4 hours. The levels of
SIRT1 adducts with 4-hydroxy-2-nonenol (4-HNE) and nitration of tyro-
sine residues on SIRT1 were analyzed by immunoblotting with anti–4-
HNE and anti–3-nitrotyrosine (3-NT) antibodies, respectively. Equal
amount of immunoprecipitated SIRT1 protein (100 mg) was used for
Western blotting. Relative intensity of 4-HNE/SIRT1 (B) and 3-NT/SIRT1
(C ) represents the increased post-translational modifications of SIRT1
protein in response to CSE treatment. Results are means 6 SEM of three
separate experiments (n 5 3). Significant differences are shown as
compared to controls: *P , 0.05, **P , 0.01, and ***P , 0.001.
Figure 9. Cigarette smoke extract (CSE)–mediated decrease in sirtuin
(SIRT1) level was associated with increased acetylation of RelA/p65
nuclear factor (NF)-kB. (A) Monocyte–macrophage (MonoMac6) cells
were treated with CSE (0.5 and 1.0%) for 4 hours. Acetylation of the
lysine residue (K310) on RelA/p65 NF-kB protein was determined in
soluble nuclear proteins (30 mg) by Western blotting using anti–acetyl
RelA/p65 (K310) antibody. b-Actin was measured as a loading control.
Lamin B (nuclear envelope protein) and the absence of the cytoskeletal
protein a-tubulin (bands not shown) were measured to confirm the
purity of nuclear extracts. (B) The relative density (% of control) of
acetylated RelA/p65 NF-kB in nuclear fraction of MonoMac6 cells
showed increased acetylation of RelA/p65 NF-kB in response to CSE
treatment at 4 hours. Each histogram represents the means 6 SEM
(n 5 3). ***P , 0.001, compared with control values.
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the decreased levels of SIRT1 may result in an NF-kB–mediated
abnormal chronic inflammatory effect, which is observed in lungs
of smokers and patients with COPD. Consistent with this notion,
we observed the decreased levels of SIRT1 and increased acti-
vation of RelA/p65 in peripheral lungs of smokers and patients
with COPD. The importance of SIRT1 further gains credence
from the observation of McBurney and colleagues (37) that
genetic ablation of SIRT1 leads to increased neutrophil infiltra-
tion in mouse lung, suggesting that knockdown of SIRT1 leads to
exaggerated lung inflammation. Therefore, it is possible that
CS-mediated reduction in SIRT1 may in part be responsible for
increased neutrophil influx, NF-kB activation, and inflammatory
response seen in lungs of smokers and patients with COPD.
We further determined the molecular mechanism of SIRT1
reduction and its role in proinflammatory cytokine release in
response to CS exposure in humanmacrophage-like cells (Mono-
Mac6) in vitro. Alveolar macrophages are considered to be
important cells in perpetuating the inflammatory response of
CS (6, 24, 38).CSE treatment significantly increased the release of
proinflammatory cytokine IL-8 concomitant with decreased
levels of SIRT1 protein and mRNA expression in MonoMac6
cells. Recently, Yang and coworkers (21) reported that CS-
mediated decrease in SIRT1 levels was correlatedwith decreased
SIRT1 activity in macrophages and rat lungs. Because this de-
crease was correlated with increased release of IL-8, we specu-
lated that CSE-mediated decrease in the levels of SIRT1 plays an
important role in release of proinflammatory cytokines. To
support this observation and to determine the specific effect of
SIRT1 in CS-induced proinflammatory cytokine release, further
experiments were performed on MonoMac6 cells by knocking
down SIRT1 or overexpressing SIRT1 as well as using a SIRT1
defective mutant lacking deacetylase activity. Knockdown of
endogenous SIRT1 and mutation of SIRT1 deacetylase domain
augmented the CS-stimulated proinflammatory cytokine (IL-8)
release, whereas SIRT1 overexpression resulted in decreased
IL-8 release in response to CSE exposure. We have previously
shown that pharmacologic activation of SIRT1 reduced the CSE-
mediated IL-8 release in MonoMac6 cells (21) and the present
findings further support these observations and emphasize the
importance of SIRT1 in regulation of proinflammatory medi-
ators, such as IL-8 and other NF-kB–dependent genes (matrix
metalloproteinases, growth factors, andmucin genes). Themech-
anismwherebyCS alters the levels of SIRT1 is not known, but it is
possible that SIRT1 is regulated by post-translational modifica-
tions and/or by kinase signaling mechanisms. The other possible
mechanism would be nucleocytoplasmic shuttling of SIRT1 by
kinase signaling mechanism leading to proteasomal degradation
of SIRT1 in the cytoplasm.
It is well known that CS-induced oxidative stress is responsible
for proinflammatory cytokine release in the lung (39). Previously,
we have shown that levels of lipid peroxidation products, such as
4-HNE, were increased in lungs of patients with COPD (40).
Post-translational modifications of various proteins by oxidative/
nitrosative stress have been shown to have influence on various
cellular functions (25, 41, 42). To determine the CS-mediated
reduction inSIRT1 levels and its post-translationalmodifications,
SIRT1 modification was evaluated by measuring the SIRT1
adducts with 4-HNE (reactive aldehydes which form protein
carbonyls), a highly reactive diffusible product of lipid peroxida-
tion and a key mediator of oxidant-induced cell signaling and
apoptosis (43). SIRT1 adducts with 4-HNEand 3-nitrotyrosine in
lungs were increased in smokers and patients with COPD
compared with nonsmokers. CSE induced the formation of
SIRT1–4-HNE adducts in MonoMac6 cells. Cysteine, histidine,
and lysine, the three nucleophilic amino acids, have been shown
to be the target of modification by 4-HNE (43). The high affinity
of 4-HNE toward lysine becomes important with respect to
SIRT1, because lysine residues 1020/1024 present on the active
site domain of SIRT1 may be the direct target of 4-HNE. Thus,
the increased SIRT1–4-HNE adduct formation seen after smoke
exposuremay therefore formapart of themechanism responsible
for the reduction in SIRT1 activity/level. However, it may also be
possible that other residues, such as cysteine(s), present onSIRT1
are involved in formation of SIRT1–4-HNE adducts. Both
oxidation and nitration can damage proteins; nitration of protein
tyrosine residues to form 3-nitrotyrosine is considered a hallmark
of tissue injury causedby inflammation (41, 42).Post-translationally
modifiedproteins canbe adirect target of proteolytic degradation
and removal (44). The increased SIRT1 protein tyrosine nitration
seen after CSE exposure in MonoMac6 cells may trigger in-
creased proteolytic degradation of this protein, resulting in de-
creased SIRT1 levels. Thus, the decreased SIRT1 levels in
smokers and patients with COPD may be explained on the basis
of the CS-mediated oxidative/nitrosative (which occurs in
patients with COPD) alterations on the SIRT1 proteins. In view
of the fact that SIRT1 is an antiaging and antiinflammatory
molecule (9, 15), the CS-mediated SIRT1modification/reduction
may have a role in lung inflammation and aging seen in patients
with COPD (3, 4, 7). However, it remains to be determined
whether SIRT1 reduction is directly associatedwith the decline in
lung function in smokers or disease progression/severity of
COPD. Because some of the patients with COPD were ex-
Figure 10. siRNA silencing of sirtuin (SIRT1) augmented the cigarette
smoke extract (CSE)–mediated acetylation of RelA/p65 nuclear factor
(NF)-kB. Monocyte–macrophage (MonoMac6) cells were transfected
with predesigned human SIRT1 siRNA duplex (100 nM) using Dhar-
maFect2 transfection reagent for 36–48 hours and then treated with
CSE (0.5%) for 12 hours. Nontargeting scrambled siRNA was used as
a negative control. Actin was measured as a loading control. (A)
Acetylation of RelA/p65 NF-kB was determined using rabbit anti-Ac-
RelA/p65 (K310) antibody in the soluble nuclear extract. The purity of
nuclear extract was shown by the presence of lamin B (nuclear
envelope protein) and the absence of the cytoskeletal protein a-tubulin
(bands not shown). (B) The relative level (% of control) of Ac-RelA/p65
showed increased acetylation of nuclear RelA/p65 in response to SIRT1
knockdown and/or CSE treatment. Each value is the mean 6 SEM of
triplicate determinations (n 5 3). ***P , 0.001, significant compared
with control.
868 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 177 2008
smokers and some of them were receiving inhaled steroids, it is
likely that, once initiated, the alterations of SIRT1 may not be
fully reversible (irreversible epigenetic events), which in turn
might beone contributor to the persistence ofmany inflammatory
changes observed even after cessation of smoking.
Reduction/inactivation of other deacetylases, such as HDACs,
has been reported to cause transactivation of NF-kB and in-
duction of proinflammatory cytokine release (25, 31, 34). Re-
cently, Yeung and colleagues (19) demonstrated that SIRT1
physically interacts with the RelA/p65 subunit of NF-kB and
inhibits gene transcription by deacetylating RelA/p65 at lysine
310, suggesting that acetylated lysine 310 might form a platform
for the binding of a bromodomain-containing protein that is
required for full transcriptional activity of RelA/p65 (45, 46).
Because acetylation at lysine 310 is required for full transactiva-
tion function of RelA/p65 (32, 33), the levels of acetylated lysine
310 moiety of RelA/p65 subunit of NF-kB in CSE-treated
MonoMac6 cells were determined. It was found that CS-mediated
SIRT1 reduction was associated with increased acetylation of ly-
sine 310 moiety on RelA/p65. SIRT1 knockdown also increased
the acetylation of RelA/p65 (K310) acetylation and this effect
was further augmented by the acetylation effect of CS on RelA/
p65. Thesedata indicate thatCSEcaused acetylation ofRelA/p65
NF-kB by reduction of SIRT1 deacetylase level and/or post-
translational modifications of its lysine residues. Therefore,
increased post-translational modifications of SIRT1 lead to dis-
ruption of RelA/p65-SIRT1 complex, which would then culmi-
nate intoNF-kBacetylation and persistent activation ofNF-kB in
response to CSE exposure in macrophages. Apart from NF-kB
regulation, SIRT1 also regulates the stress/protective pathway
via deacetylation of the forkhead box class (FOXO3) transcrip-
tion factor. SIRT1 reduction leads to acetylation of FOXO3,
which would then result in loss of its transcription activity for
transcription of GADD45 (DNA repair) and MnSOD genes
(9). Therefore, loss of SIRT1 by CS will lead to acetylation of
FOXO3 and tumor suppressor p53, resulting in lung cell senes-
cence and apoptosis.
In conclusion, we have shown for the first time that the level of
nuclear SIRT1 protein was decreased in peripheral lung tissue of
smokers and patients with COPD. SIRT1 proteins undergo post-
translational covalent modifications in response to CS exposure,
which may not be fully reversible. These changes render SIRT1
inactive, leading to acetylation/activation of RelA/p65, and
thereby uncontrolled expression of proinflammatory mediators,
which is seen in macrophages/lungs of smokers and patients with
COPD. In view of the role of SIRT1 in regulation of proinflam-
matory mediators, apoptosis, senescence, cell survival, differen-
tiation, and aging, it is tempting to propose that CS-mediated
alterations in SIRT1 would have ramifications on these processes
that are directly linked to the pathogenesis of COPD (4–6, 8, 24).
Further studies are required to understand the mechanism of
CS-mediated down-regulation of SIRT1 and its involvement in
chronic inflammatory and injurious processes in the lung using
genetic gain and loss of function, and whether up-regulation or
genetic modifications of SIRT1 can attenuate such processes in
animal models of COPD.
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